Background: Anti‐IgE therapy can serve as an option for inadequately controlled seasonal allergic rhinitis (SAR) patients. LP‐003, a novel anti‐IgE antibody, is being tested as an add‐on treatment for SAR. This trial aimed to evaluate whether LP‐003 is effective and safe for SAR.Methods: This placebo‐controlled double‐blind phase 2 randomized clinical trial was conducted in 17 hospitals in China. SAR patients whose symptoms were inadequately controlled despite first‐line treatment (nasal corticosteroids with or without oral antihistamine) in the previous two seasons were enrolled between July 6, 2023 and August 7, 2023. Participants were randomized in a ratio of 2:4:3 to receive subcutaneous injections of 100 mg LP‐003, 200 mg LP‐003 or placebo every 4 weeks for 2 doses. All patients received fluticasone propionate as standard‐of‐care (SoC). The main outcome was the mean total nasal symptom score (TNSS) during the peak pollen period (PPP). Secondary endpoints included a series of symptom and medication scores, quality of life assessments during PPP and pollen period (PP), immunogenicity and safety.Results: A total of 180 participants were randomly assigned. The LP‐003 + SoC treatment achieved a significantly lower TNSS compared with placebo + SoC (3.31 vs. 4.06, intergroup difference = −0.74, p = 0.0464). For key secondary outcomes, the LP‐003 group also achieved significantly lower daily nasal symptom and rescue medication use scores (3.54 vs. 4.42, intergroup difference = −0.88, p = 0.0352), and daily ocular symptom and rescue medication use scores (1.66 vs. 2.19, intergroup difference = −0.54, p = 0.0245) compared to the placebo group. The suppression of free IgE was prevalent and persistent. There was no statistically significant difference in adverse events and severe adverse events between LP‐003 and placebo groups.Conclusions: These findings support LP‐003 as a promising add‐on option to the SoC for patients with moderate to severe SAR. Fixed dosage regimen and extensive suppression of free‐IgE render it a cutting‐edge advantage.
16 October 2024 in JMIR Public Health and Surveillance
Background: Allergic diseases are associated with an increased susceptibility to respiratory tract infections. Although allergen immunotherapy (AIT) alters the course of allergies, there is limited evidence from clinical practice demonstrating its ability to enhance the host defense against pathogens. Objective: The aim of this study was to investigate the protective effect of AIT against viral infection in patients with allergic rhinitis (AR) and allergic asthma (AS) based on clinical evidence. Methods: A multicenter, questionnaire-based survey was conducted during a tremendous surge in COVID-19 cases between February 10, 2023, and March 15, 2023, in 81 centers across China recruiting healthy volunteers and patients with AR and AS to investigate the clinical outcomes of COVID-19 infection. Results: Of 10,151 participants recruited in the survey, 3654 patients and 2192 healthy volunteers who tested positive for COVID-19 were included in this analysis after screening. Overall, no significant differences in COVID-19 outcomes were observed between patients and healthy volunteers. An additional 451 patients were excluded due to their use of biologics as the sole add-on treatment, leaving 3203 patients in the further analysis. Of them, 1752 were undergoing routine medication treatment (RMT; the RMT group), whereas 1057 and 394 were receiving AIT and a combination of AIT and omalizumab (OMA) as adjunct therapies to RMT, respectively (AIT+RMT and AIT+OMA+RMT groups). The AIT group showed milder COVID-19 symptoms, shorter recovery periods, and a lower likelihood of hospitalization or emergency department visits than the RMT group (all P<.05). After adjusting for confounding factors, including demographic characteristics and COVID-19 vaccination, AIT remained a significant protective factor associated with shorter recovery time (adjusted odds ratio [OR] 0.62, 95% CI 0.52‐0.75; adjusted P<.001) and a lower incidence of hospitalization or emergency department visits (adjusted OR 0.73, 95% CI 0.54‐0.98; adjusted P=.03). Furthermore, the AIT+OMA+RMT group showed greater protection with a shorter recovery time (adjusted OR 0.51, 95% CI 0.34‐0.74; adjusted P<.001) than the AIT+RMT group. Conclusions: Our multicenter observational study provides valuable clinical evidence supporting the protective effect of AIT against COVID-19 infection in patients with AR and AS.
Allergic rhinitis (AR) is a common inflammatory disorder of the nasal mucosa, usually triggered by environmental allergens. Indolepropionic acid (IPA) can influence immune responses; however, the specific mechanisms underlying the effects of IPA on immune regulation in AR remain largely unexplored. In the present study, an experimental mouse model of AR was established by sensitizing and exposing the mice to allergens, followed by the administration of IPA via gavage. Nasal symptoms were assessed through behavioral scoring, histological examinations were conducted to evaluate changes in nasal mucosa, and cytokine levels were quantified using ELISA. The expression of key signaling molecules was analyzed by immunohistochemistry, reverse transcription‑quantitative PCR and western blotting. Additionally, the effects of IPA combined with an AKT inhibitor (HY‑10355) on signaling pathway‑related proteins in human nasal epithelial cells were evaluated using cellular immunofluorescence and western blotting. The results revealed that IPA treatment significantly reduced nasal inflammation, as indicated by decreased sneezing and mucus secretion. Histological analysis showed reduced inflammatory cell infiltration and epithelial damage in IPA‑treated mice compared to controls. Furthermore, cytokine analysis revealed reduced levels of the pro‑inflammatory cytokines IL‑4, IL‑5, IL‑13 and immunoglobulin E, along with increased levels of the anti‑inflammatory cytokine IL‑10. Molecular investigations demonstrated that IPA can activate the AKT/CCAAT enhancer binding protein β pathway, leading to increased IL‑10 expression and reduced inflammation. In conclusion, these findings suggested that IPA may serve as a promising therapeutic strategy for managing AR, pending further clinical validation.
Background: Mounting evidence supports the efficacy of sublingual immunotherapy (SLIT) due to its favorable safety profile and convenience. However, there is limited research comparing the efficacy and safety of SLIT between adults and children. Objective: The aim of this prospective study is to contribute additional corroborative findings by evaluating the efficacy and safety of a SLIT vaccine formulated with Artemisia annua extracts in children and adult patients with seasonal allergic rhinoconjunctivitis (SARC). Methods: SARC patients (n = 75, SLIT group: 49, control group: 26) allergic to Artemisia were treated with a standardized SLIT or symptomatic drug following the end of the grass pollen season in 2022. Evaluation of the efficacy of SLIT during the peak pollen phase (PPP) in 2023 was based on combined scores of medication and rhinoconjunctivitis symptom (CSMRS) and visual analog scale (VAS). Tolerability assessment was based on the incidence of local or systemic reactions. Results: Compared with the control group, the SLIT group showed significant improvement in CSMRS after 1 year of treatment with Artemisia annua-SLIT (P < 0.001). Besides, Artemisia annua-SLIT significantly reduced VAS to a greater level from baseline (P < 0.001) than pharmacotherapy (P < 0.01) at the PPP in 2023. Meanwhile, our observations revealed no significant differences in CSMRS or VAS between the monosensitized group (n = 14) and polysensitized group (n = 35), as well as between the 0.05). No severe systemic adverse events (AEs) were reported. Overall, 20/49 patients experienced mild to moderate treatment-related adverse events (TRAEs) following Artemisia annua-SLIT. In the <18 age group, 20% of patients (3/15) experienced TRAEs, while in the ≥18 age group, 50% of patients (17/34) experienced TRAEs. Conclusion: For patients suffering from SARC, Artemisia annua-SLIT demonstrates significant therapeutic efficacy and an excellent safety profile. Notably, we have provided the first evidence that the efficacy of Artemisia annua-SLIT is consistent across both adult and pediatric populations.